Deals: Page 6

  • The AbbVie logo is prominently displayed on the facade of a sleek, contemporary building surrounded by a clear blue sky.
    Image attribution tooltip
    Alamy
    Image attribution tooltip
    Immune reset

    AbbVie to buy CAR-T developer Capstan in deal worth up to $2.1B

    The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of the difficulties presented by current cell treatments.

    By Ned Pagliarulo • June 30, 2025
  • A scientist works in a Kymera Therapeutics lab.
    Image attribution tooltip
    Permission granted by Jen Randall / Kymera Therapeutics
    Image attribution tooltip

    Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

    The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a new drug prospect, meanwhile.

    By • June 25, 2025
  • A white sign with the word Lilly written in red stands outside of an office.
    Image attribution tooltip
    Scott Olson via Getty Images
    Image attribution tooltip
    Gene editing

    Lilly to acquire Verve in $1B bet on gene editing for heart disease

    The deal centers around a medicine that could “shift the treatment paradigm for cardiovascular disease,” Lilly said, but also follows a yearslong decline in Verve’s share price amid skepticism over the need for such a therapy. 

    By Kristin Jensen • June 17, 2025
  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Sage, following setbacks, to sell to Supernus for $561M

    In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that depressed its stock price.

    By • June 16, 2025
  • A photo of CureVac headquarters in Tuebingen, Germany
    Image attribution tooltip
    Courtesy of CureVac AG
    Image attribution tooltip

    BioNTech buys mRNA, courtroom rival CureVac in all-stock deal

    Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed CureVac in ongoing patent litigation. 

    By • June 13, 2025
  • An illustration of lymphocytes
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Immune reset

    Cullinan doubles down on bispecifics for autoimmune disease with Genrix deal

    The deal gives Cullinan T cell engagers aimed at BCMA and CD19, which drugmakers are exploring as possible targets for antibody- and cell-based drugs for inflammatory conditions.

    By Kristin Jensen • June 5, 2025
  • An Eli Lilly logo is seen at the top of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Lilly partners with Camurus in search of a long-lasting obesity drug

    The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help extend the durability of up to four of its weight-loss medicines.

    By Kristin Jensen • June 4, 2025
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi to acquire Blueprint for up to $9.5B

    The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.

    By • June 2, 2025
  • A microscopic view of a nerve cell, containing magenta dots on a blue and black wave texture background.
    Image attribution tooltip
    Courtesy of Nwasinachi Adriana Ezeji/Center for Advanced Pain Studies, University of Texas, Dallas
    Image attribution tooltip
    Pain drugs

    Lilly to buy pain drug developer SiteOne, challenging Vertex

    The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

    By • May 27, 2025
  • An illustration of beta amyloid plaques and tau in the brain
    Image attribution tooltip
    National Institute on Aging. (2017). "Beta-Amyloid Plaques and Tau in the Brain" [Image]. Retrieved from Flickr.
    Image attribution tooltip

    Sanofi gains experimental Alzheimer’s drug through Vigil buyout

    Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing a total deal value of $470 million.

    By • May 22, 2025
  • Pfizer HQ entrance
    Image attribution tooltip
    Permission granted by Pfizer
    Image attribution tooltip
    China competition

    Pfizer buys into PD-1/VEGF competition with 3SBio deal

    Pfizer will pay China’s 3SBio $1.25 billion up front to access a cancer drug that could rival Akeso and Summit’s closely watched immunotherapy ivonescimab.

    By • May 20, 2025
  • 23andMe
    Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    Regeneron wins bid to buy 23andMe out of bankruptcy

    The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm 23andMe's assets for $256 million.

    By Ned Pagliarulo • May 19, 2025
  • Illustration of medical pills
    Image attribution tooltip
    Permission granted by PHIL
    Image attribution tooltip
    Sponsored by PHIL

    Bridging the data gaps that impact retail and specialty-lite success

    Learn how to leverage predictive analytics and measure top KPIs to maximize patient outcomes, provider engagement and brand performance on this webinar from PHIL and Syneos Health.

    May 19, 2025
  • A white office building bearing a sign for BioMarin Pharmaceutical stands against a blue sky.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    BioMarin to buy rare disease drugmaker Inozyme for $270M

    The deal “fits like a glove” for BioMarin’s business, according to an analyst who also thinks there could be a “valuable” market opportunity for Inozyme’s main drug.

    By • May 16, 2025
  • A Novo Nordisk sign is seen on the side of a building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Obesity drugs

    Novo to work with Septerna in hunt for oral obesity drugs

    The research collaboration, under which Septerna will receive more than $200 million in upfront and near-term fees, is the latest deal Novo has struck to expand its obesity pipeline.

    By • May 14, 2025
  • A sign with the letters GSK hangs on the side of an office building.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    GSK to buy liver disease drug for $1.2B

    With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver disease franchise.

    By Kristin Jensen • May 14, 2025
  • Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    Facing ‘uncertainty on steroids,’ biotech dealmakers tread more cautiously

    Experts say market turmoil has made it harder for buyers and sellers to agree on price, which can be an especially imposing obstacle to large acquisitions.

    By • May 6, 2025
  • Scientists working in an R&D laboratory
    Image attribution tooltip
    Courtesy of Merck KGaA
    Image attribution tooltip

    Merck KGaA to buy biotech SpringWorks for $3.9B

    The deal, which has been in the works for months, hands the German pharmaceutical company two approved drugs for rare tumors.

    By Ned Pagliarulo • April 28, 2025
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip
    China competition

    Sanofi licenses immune disease drugs from startup Earendil

    The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at multiple popular immune disease targets, such as TL1A and IL23. 

    By Kristin Jensen • April 17, 2025
  • A double exposure photo illustration of a glass flask and a scientist holding a tube in a laboratory, with stock market information in the background.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip

    Tempest seeks strategic alternatives as cash runs out for Phase 3 trial

    Amid a funding drought for startups, the company is looking for a deal that can advance its liver cancer drug.

    By • April 10, 2025
  • An illustration of astrocytes forming the blood-brain barrier.
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    Brain drug revival

    GSK targets neurodegenerative diseases with latest licensing deal

    The pharma giant is wagering potentially billions of dollars on technology from ABL Bio that’s designed to get drugs across the blood-brain barrier.

    By • April 7, 2025
  • Image attribution tooltip
    Spencer Platt via Getty Images
    Image attribution tooltip

    M&A recap: Big pharma starts the year mostly avoiding billion-dollar deals

    Just two acquisitions in the first quarter, that of Intra-Cellular Therapies and IDRx, crossed the $1 billion mark, a notable decrease from the six seen during the same period last year.

    By • April 4, 2025
  • A photo of Bluebird bio employees in a laboratory.
    Image attribution tooltip
    Courtesy of Bluebird bio
    Image attribution tooltip

    Bluebird gets rival takeout offer from Ayrmid

    The new bid surpasses an offer SK Capital and Carlyle Group made last month for the gene therapy developer, which Bluebird’s board still supports.

    By • March 28, 2025
  • Red human heart drawing on blue background
    Image attribution tooltip
    Getty Images
    Image attribution tooltip
    China competition

    Merck bets $200M on a new type of heart pill

    A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a genetic risk factor called lipoprotein(a). 

    By • March 25, 2025
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip
    Immune reset

    Sanofi wagers $600M on a dual-targeting antibody drug for autoimmune disease

    The deal with startup Dren Bio hands Sanofi a so-called myeloid cell engager that would compete with an array of programs aiming to “reset” the immune systems of people with inflammatory conditions. 

    By Kristin Jensen • March 20, 2025